neutralizing antibody titers against the SARS-CoV-2 spike protein and nucleocapsid protein on day 28 after second vaccination in patients receiving active cancer treatment. ADDENDUM extra booster shot The first co-primary endpoint is the difference in SARS-CoV-2 IgG levels, before and 28 days after administration of a third dose of the COVID-19 mRNA BNT162b2 vaccine upon previous receipt of 2 doses of this vaccine. The second co-primary endpoint is the difference in SARS-CoV-2 IgG levels, before and 28 days after administration of a fourth dose of the COVID-19 mRNA BNT162b2 vaccine upon previous receipt of 3 doses of this vaccine.

neutralizing antibody titers against the SARS-CoV-2 spike protein and nucleocapsid protein on day 28 after second vaccination in patients receiving active cancer treatment. ADDENDUM extra booster shot The first co-primary endpoint is the difference in SARS-CoV-2 IgG levels, before and 28 days after administration of a third dose of the COVID-19 mRNA BNT162b2 vaccine upon previous receipt of 2 doses of this vaccine. The second co-primary endpoint is the difference in SARS-CoV-2 IgG levels, before and 28 days after administration of a fourth dose of the COVID-19 mRNA BNT162b2 vaccine upon previous receipt of 3 doses of this vaccine.